Nurix Q1 net loss $87.2M ($0.79); advancing bexobrutideg registrational program

Nurix Therapeutics, Inc.

2026-Q1 EPS reported -$0.79 revenue$6,252,000

Revenue $6.3M vs $18.5M YoY; net loss $87.2M ($0.79) vs $56.4M ($0.67).
Cash $540.7M vs $592.9M at Nov 30, 2025; net burn ~$52M in quarter.
Enrolling Phase 2 DAYBreak CLL-201 for bexobrutideg; Phase 3 confirmatory trial planned mid-2026.
Healthy volunteer SAD/MAD study of new tablet formulation to support IND in immunology/inflammation.
Sanofi advancing STAT6 degrader NX-3911; Gilead advancing IRAK4 degrader GS-6791 in Phase 1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nurix Therapeutics, Inc. reported the fiscal quarter ended February 28, 2026 results: revenue $6.3 million.

Period: the fiscal quarter ended February 28, 2026
Revenue: $6.3 million
Result: reported results

Exact text from the filing

Revenue for the three months ended February 28, 2026, was $6.3 million

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001549595-26-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.